Close Menu

Myriad

The new additions reflect data published this summer in the TAILORx trial, which speak to the chemopredictive ability of Genomic Health's Oncotype DX.

breast cancer patient taking chemotherapy

Although a draft guidance last month recommended against use of molecular tests to guide chemotherapy, the group's finalized decision is subject to price negotiation and other adjustments.

The first randomized study to show a PARP inhibitor benefits advanced breast cancer patients is also a sign of the expanding utility of BRCA testing in precision medicine.

The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.

Pages